Clinically applicable inhibitors impacting genome stability
View/ Open
Full Text
Date
2018-05-13Author
Prakash, Anu
Garcia-Moreno, Juan
Brown, James
Bourke, Emer
Metadata
Show full item recordUsage
This item's downloads: 0 (view details)
Cited 6 times in Scopus (view citations)
Recommended Citation
Prakash, Anu; Garcia-Moreno, Juan; Brown, James; Bourke, Emer (2018). Clinically applicable inhibitors impacting genome stability. Molecules 23 (5),
Published Version
Abstract
Advances in technology have facilitated the molecular profiling (genomic and transcriptomic) of tumours, and has led to improved stratification of patients and the individualisation of treatment regimes. To fully realize the potential of truly personalised treatment options, we need targeted therapies that precisely disrupt the compensatory pathways identified by profiling which allow tumours to survive or gain resistance to treatments. Here, we discuss recent advances in novel therapies that impact the genome (chromosomes and chromatin), pathways targeted and the stage of the pathways targeted. The current state of research will be discussed, with a focus on compounds that have advanced into trials (clinical and pre-clinical). We will discuss inhibitors of specific DNA damage responses and other genome stability pathways, including those in development, which are likely to synergistically combine with current therapeutic options. Tumour profiling data, combined with the knowledge of new treatments that affect the regulation of essential tumour signalling pathways, is revealing fundamental insights into cancer progression and resistance mechanisms. This is the forefront of the next evolution of advanced oncology medicine that will ultimately lead to improved survival and may, one day, result in many cancers becoming chronic conditions, rather than fatal diseases.
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland
Related items
Showing items related by title, author, creator and subject.
-
Short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting
Shao, YL; Yee, KH; Koh, SK; Wong, YF; Yeoh, LY; Low, S; Sum, CF (Singapore Medical Journal, 2017-10-12)INTRODUCTION We aimed to evaluate the effectiveness and safety of canagliflozin as compared to sitagliptin in a real-world setting among multiethnic patients with Type 2 diabetes mellitus (T2DM) in Singapore. METHODS This ... -
Effect of sodium glucose co-transporter-2 inhibition on the Aldosterone/Renin Ratio in Type 2 Diabetes Mellitus
Griffin, Tomás P.; Islam, Md Nahidul; Blake, Liam; Bell, Marcia; Griffin, Matthew D.; O’Shea, Paula M. (Thieme Publishing, 2018-12-06)The aldosterone to renin ratio (ARR) is recommended for case detection of primary aldosteronism (PA). Several factors including medications can undermine its diagnostic accuracy. The objective was to explore the effect of ... -
Oxidative phosphorylation and the tricarboxylic acid cycle are essential for normal development of mouse ovarian follicles
Wycherley, G. (Oxford University Press (OUP), 2005-06-24)BACKGROUND: Mouse ovarian follicles are typically grown in upright drops of culture medium. Recently we found that culture of follicles at the medium-gas interface in inverted drops markedly improved follicular development, ...